{"classes":[{"categories":[{"measurements":[{"comment":"The study was ended prematurely due to poor accrual and only two patients progressed while the rest were lost to follow up. The statistical analysis will not give a reliable range except median based on two findings","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"307"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Length of subject survival after starting study treatment","dispersionType":"Inter-Quartile Range","groups":[{"description":"Once eligibility is confirmed, the patient will start treatment cycles with Pembrolizumab at 200 mg given intravenously on the first day of each cycle. Each cycle corresponds to a duration of 3 weeks.\n\nPembrolizumab: Pembrolizumab will be administered intravenously every 3 weeks.","id":"OG000","title":"Pembrolizumab 200 mg"}],"paramType":"MEDIAN","populationDescription":"Due to poor accrual, low sample size, and higher number of patients censored, the 95% CI for median OS and PFS could not be determined.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"days"}